The companies anticipate finalising the acquisition in the third quarter of 2026.

Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business ...

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

For decades, there has been no cure and few treatment options.

The drug givinostat - used for Duchenne Muscular Dystrophy management - remains unavailable to boys and young men who can no ...

Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...

Parents of children with Duchenne muscular dystrophy, who had been protesting for 45 nights outside the Government ...

Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...

Add Yahoo as a preferred source to see more of our stories on Google. When Conner Curran was first diagnosed with Duchenne muscular dystrophy at age 4, his parents were told there was nothing they ...

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say ...

Parents of children diagnosed with Duchenne muscular dystrophy are meeting with Georgian Prime Minister Irakli Kobakhidze at ...

The most commonly diagnosed form of muscular dystrophy, Duchenne is a genetic disease that affects mostly boys and causes progressive muscle weakness over time. Its early physical signs tend to be ...